Use of human intravenous immunoglobulin for the treatment of 12 dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia

IF 1.7 2区 农林科学 Q2 VETERINARY SCIENCES Journal of Small Animal Practice Pub Date : 2024-01-19 DOI:10.1111/jsap.13700
E. Stikeman, D. Bianco
{"title":"Use of human intravenous immunoglobulin for the treatment of 12 dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia","authors":"E. Stikeman,&nbsp;D. Bianco","doi":"10.1111/jsap.13700","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To evaluate the safety and efficacy of human intravenous immunoglobulin in dogs with newly diagnosed malignancy and presumed secondary immune-mediated thrombocytopenia.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Twelve client-owned dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia were prospectively enrolled to receive a single infusion of human intravenous immunoglobulin at a dose of 0.5 to 1 mg/kg intravenous over 8 hours. A complete treatment response was defined as a platelet estimation of ≥40,000 platelets/μL within 24 hours and a partial response within 48 hours from the completion of human intravenous immunoglobulin infusion. No treatment response was defined as a platelet estimation remaining &lt;40,000 platelets/μL over 48 hours from the completion of the human intravenous immunoglobulin infusion. This pilot study had a prospective, open-label, uncontrolled design.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Out of the 12 enrolled dogs, seven completed the study. A complete treatment response to human intravenous immunoglobulin was identified in one lymphoma dog and a partial response was noted in another lymphoma dog. The remaining 10 dogs had no response to human intravenous immunoglobulin. No clinically relevant adverse reactions to human intravenous immunoglobulin occurred in any of the 12 initially enrolled dogs during the infusion and over a 3-month follow-up period for the seven surviving dogs.</p>\n </section>\n \n <section>\n \n <h3> Clinical Significance</h3>\n \n <p>The results of this study suggest that the use of human intravenous immunoglobulin in dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia appears safe, but not effective for the treatment of thrombocytopenia. Larger multi-centre, prospective, double-blinded, placebo-controlled, outcome-based, malignancy-specific studies are needed to further evaluate these preliminary findings.</p>\n </section>\n </div>","PeriodicalId":17062,"journal":{"name":"Journal of Small Animal Practice","volume":"65 5","pages":"338-345"},"PeriodicalIF":1.7000,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Small Animal Practice","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jsap.13700","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To evaluate the safety and efficacy of human intravenous immunoglobulin in dogs with newly diagnosed malignancy and presumed secondary immune-mediated thrombocytopenia.

Materials and Methods

Twelve client-owned dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia were prospectively enrolled to receive a single infusion of human intravenous immunoglobulin at a dose of 0.5 to 1 mg/kg intravenous over 8 hours. A complete treatment response was defined as a platelet estimation of ≥40,000 platelets/μL within 24 hours and a partial response within 48 hours from the completion of human intravenous immunoglobulin infusion. No treatment response was defined as a platelet estimation remaining <40,000 platelets/μL over 48 hours from the completion of the human intravenous immunoglobulin infusion. This pilot study had a prospective, open-label, uncontrolled design.

Results

Out of the 12 enrolled dogs, seven completed the study. A complete treatment response to human intravenous immunoglobulin was identified in one lymphoma dog and a partial response was noted in another lymphoma dog. The remaining 10 dogs had no response to human intravenous immunoglobulin. No clinically relevant adverse reactions to human intravenous immunoglobulin occurred in any of the 12 initially enrolled dogs during the infusion and over a 3-month follow-up period for the seven surviving dogs.

Clinical Significance

The results of this study suggest that the use of human intravenous immunoglobulin in dogs with newly diagnosed malignant disease and presumed secondary immune-mediated thrombocytopenia appears safe, but not effective for the treatment of thrombocytopenia. Larger multi-centre, prospective, double-blinded, placebo-controlled, outcome-based, malignancy-specific studies are needed to further evaluate these preliminary findings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用人静脉注射免疫球蛋白治疗 12 只患有新诊断恶性疾病和假定继发性免疫介导血小板减少症的狗。
目的评估人静脉注射免疫球蛋白对新诊断为恶性肿瘤和假定继发性免疫介导的血小板减少症的狗的安全性和有效性:12只新诊断为恶性疾病和假定为继发性免疫介导的血小板减少症的客户自养犬被纳入前瞻性研究,接受单次静脉注射人免疫球蛋白,剂量为0.5至1毫克/千克,静脉注射时间为8小时。完全治疗反应的定义是,在输注人静脉注射免疫球蛋白后的 24 小时内,血小板估计值≥40,000 个/μL;在输注人静脉注射免疫球蛋白后的 48 小时内,血小板估计值≥40,000 个/μL。无治疗反应的定义是血小板估计值剩余 结果:在 12 只入选犬中,有 7 只完成了研究。其中一只淋巴瘤犬对人静脉注射免疫球蛋白的治疗完全应答,另一只淋巴瘤犬出现部分应答。其余 10 只犬对静脉注射人免疫球蛋白没有反应。在输注期间以及对 7 只存活犬进行的为期 3 个月的随访期间,12 只最初入选的犬均未出现与人静脉注射免疫球蛋白相关的临床不良反应:这项研究的结果表明,对新诊断为恶性疾病和假定继发性免疫介导血小板减少症的狗使用人静脉注射免疫球蛋白似乎是安全的,但对治疗血小板减少症效果不佳。需要进行更大规模的多中心、前瞻性、双盲、安慰剂对照、以结果为基础、针对特定恶性疾病的研究,以进一步评估这些初步发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Small Animal Practice
Journal of Small Animal Practice 农林科学-兽医学
CiteScore
3.30
自引率
6.20%
发文量
117
审稿时长
12-24 weeks
期刊介绍: Journal of Small Animal Practice (JSAP) is a monthly peer-reviewed publication integrating clinical research papers and case reports from international sources, covering all aspects of medicine and surgery relating to dogs, cats and other small animals. These papers facilitate the dissemination and implementation of new ideas and techniques relating to clinical veterinary practice, with the ultimate aim of promoting best practice. JSAP publishes high quality original articles, as well as other scientific and educational information. New developments are placed in perspective, encompassing new concepts and peer commentary. The target audience is veterinarians primarily engaged in the practise of small animal medicine and surgery. In addition to original articles, JSAP will publish invited editorials (relating to a manuscript in the same issue or a topic of current interest), review articles, which provide in-depth discussion of important clinical issues, and other scientific and educational information from around the world. The final decision on publication of a manuscript rests with the Editorial Board and ultimately with the Editor. All papers, regardless of type, represent the opinion of the authors and not necessarily that of the Editor, the Association or the Publisher. The Journal of Small Animal Practice is published on behalf of the British Small Animal Veterinary Association and is also the official scientific journal of the World Small Animal Veterinary Association
期刊最新文献
Minimally invasive technique to facilitate ultrasound-guided removal of migrating foreign bodies: eight cases (2022). Surgical management of a cervical oesophageal duplication cyst with tracheal communication in a dog. Hyperfibrinolysis in a dog with strongyloidiasis. Prevalence and antimicrobial susceptibility profile of uropathogens in dogs and cats with signs of urinary tract infection. Issue Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1